ELICERA THERAPEUTICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.92 SEK | -2.13% |
|
+0.22% | -79.82% |
| Mar. 28 | Elicera Therapeutics AB Announces Director Changes | CI |
| Mar. 06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 32.99M 3.04M |
|---|---|---|---|---|---|
| Net income 2024 * | -48M -4.42M | Net income 2025 * | -34M -3.13M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 35M 3.22M | Net cash position 2025 * | 41M 3.78M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
-0.55
x | Employees | 2 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 38.42% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.13% | ||
| 1 week | +0.22% | ||
| Current month | -2.13% | ||
| 1 month | -20.35% | ||
| 3 months | -45.88% | ||
| 6 months | -79.56% | ||
| Current year | -79.82% |
1 week
0.89
0.99
1 month
0.891.28
Current year
0.895.80
1 year
0.897.24
3 years
0.899.00
5 years
0.899.00
10 years
0.899.00
| Managers | Title | Age | Since |
|---|---|---|---|
Magnus Essand
FOU | Founder | 60 | 13-12-31 |
Di Yu
FOU | Founder | 39 | 13-12-31 |
Jamal El-Mosleh
CEO | Chief Executive Officer | 43 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19-12-31 | |
| Director/Board Member | 73 | 19-12-31 | |
| Chairman | 68 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 0.92 | -2.13% | 47 724 |
| 24-05-10 | 0.94 | -0.84% | 20,811 |
| 24-05-08 | 0.948 | +4.41% | 80,142 |
| 24-05-07 | 0.908 | -1.09% | 214,021 |
| 24-05-06 | 0.918 | -1.29% | 42,876 |
Delayed Quote Nasdaq Stockholm, May 13, 2024 at 04:57 am EDT
More quotes
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
Sector
Pharmaceuticals
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -79.82% | 3.04M | |
| +30.38% | 684B | |
| +29.44% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.34% | 240B | |
| +9.46% | 208B | |
| -7.36% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- ELIC Stock
